1/31/2017
When: Thursday, February 1, 2018
Time: 11am EST/ 5pm EU CET
Speaker: Sandra “SAM” Sather, MS, BSN, CCRA, CCRC Expert (Clinical & Risk)
-
On December 19th, 2025, the US Food and Drug Administration released the finalized guidance for industry: Processes and Practices Applicable to Bioresearch Monitoring Inspections. The guidance details the processes and practices of Bioresearch Monitoring Program (BIMO) inspections of FDA-regulated establishments NOT specified in existing FDA guides or manuals.
-
On September 8th, 2025, the US Food and Drug Administration (FDA) released their final guidance for industry on the ICH E6(R3) Good Clinical Practice (GCP). ICH E6(R3) Principles and Annex 1 were finalized on January 6th, 2025, officially taking over the preceding 2016 ICH E6(R2). Annex 2 is expected to be finalized in early 2026.
-
On December 15th, 2025, the US Food and Drug Administration (FDA) released the finalized guidance for industry “Investigator Responsibilities — Safety Reporting for Investigational Drugs and Devices”. Unlike most updates, this finalized guidance is replacing the FDA’s recommendations from two separate final guidance documents: “Safety Reporting Requirements for INDs and BA/BE Studies” from 2012 and “Adverse Event Reporting to IRBs—Improving Human Subject Protection” from 2009, both of which are now withdrawn.
-
On July 7, 2025, the European Union (EU) Commission and Pharmaceutical Inspection Co-operation Scheme (PIC/S) published an updated draft of Annex 11: Computerised Systems, a supplementary guideline that is part of the Good Manufacturing Practice (GMP). Although it is GMP focused, the guiding principles of the annex can also be applied to other GxP standards.
-
In July, 2025, the US Food and Drug Administration (FDA) issued a warning letter to an investigator conducting a clinical trial for pediatric participants. The warning letter was the result of a routine inspection part of the FDA’s Bioresearch Monitoring Program (BIMO) as well as the investigator’s written response to the Form FDA 483.
The US Department of Health and Human Services along with 15 other agencies published an Interim Final Rule (IFR) in the Federal Register on January 22, 2017. The Interim Final Rule was made available for the public to view on January 17, 2018, and can be found here.
In an effort to improve the user experience, the National Library of Medicine (NLM) released updates to ClinicalTrials.gov on December 18, 2017. ClinicalTrials.gov is a searchable database of publicly and privately funded clinical trials being conducted globally. The information is provided by Sponsors and Investigators, and a listing does not indicate the clinical trial has been evaluated by the United States Federal Government.
What is an Early Feasibility Study?